De‐Escalation Treatment Strategies From Natalizumab in Patients With Relapsing Multiple Sclerosis in Austria
Our findings reveal an increased risk of relapses and EDSS worsening following de-escalation from NTZ. Additionally, relapse probability and EDSS progression were influenced by ARR during transition and EDSS scores at the end of the transition period.
Authors
- Christiane Gradl
- Franziska Di Pauli (ORCID: https://orcid.org/0000-0001-6183-2394)
- Bettina Heschl
- Christian Enzinger (ORCID: https://orcid.org/0000-0001-9764-7617)
- Michael Guger (ORCID: https://orcid.org/0000-0001-8219-781X)
- Erich Kvas
- Stefan Kalcher
- Thomas Berger (ORCID: https://orcid.org/0000-0001-5626-1144)
Institutions
- Johannes Kepler University of Linz (AT)
- Innsbruck Medical University (AT)
- Universität Innsbruck (AT)
- Medical University of Graz (AT)
- University of Applied Sciences St Pölten (AT)
- Medical University of Vienna (AT)
Publication Details
- Journal
- European Journal of Neurology
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1111/ene.70282
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Alexion Pharmaceuticals
- Celgene
- Neuraxpharm
- MedDay Pharmaceuticals
- Novartis Pharma
- Cilag